Gastric cancer remains a major unmet clinical problem with over 1 million new cases
worldwide. It is the fourth most commonly occurring cancer in men and the seventh most …

Gastric cancer is one of the leading causes of cancer-related death worldwide. Many
patients have inoperable disease at diagnosis or have recurrent disease after resection with …

Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of
death from cancer in the world. Several advances have been made in the staging …

The authors focused on the current surgical treatment of resectable gastric cancer, and
significance of peri-and post-operative chemo or chemoradiation. Gastric cancer is the 4 th …

Gastric cancer incidence and mortality decreased substantially over the last decades in most
countries worldwide, with differences in the trends and distribution of the main topographies …

Background A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves
survival among patients with incurable locally advanced or metastatic gastric …

Cancers arising from the esophagus, including the gastroesophageal junction, are relatively
uncommon in the United States—the lifetime risk of this cancer is 0.8 percent for men and …

Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a
platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for …

Background Gastric cancer is the fifth most common cancer worldwide. In" Western"
countries, most people are either diagnosed at an advanced stage, or develop a relapse …

Purpose In the randomized, multinational phase II/III trial (V325) of untreated advanced
gastric cancer patients, the phase II part selected docetaxel, cisplatin, and fluorouracil (DCF) …